...
首页> 外文期刊>Oxidative Medicine and Cellular Longevity >Yiqi-Huoxue Granule (YQHX) Downregulates Prothrombotic Factors by Modulating KLF2 and NF-κB in HUVECs following LPS Stimulation
【24h】

Yiqi-Huoxue Granule (YQHX) Downregulates Prothrombotic Factors by Modulating KLF2 and NF-κB in HUVECs following LPS Stimulation

机译:Yiqi-Huoxue颗粒(YQHX)通过调节LPS刺激后的HUVEC中的KLF2和NF-κB,下调普形癌细胞因子

获取原文
           

摘要

The Yiqi-Huoxue granule (YQHX) is a traditional Chinese medication widely used in the therapy of the traditional Chinese medicine diagnosis “Qi deficiency” or “blood stasis” in China. Both these symptoms are related to inflammation, but the mechanisms of YQHX against inflammation are largely unknown. Thus, our present study investigated the effects of YQHX on regulating inflammatory responses induced by lipopolysaccharides (LPS) in HUVECs. Our data found that YQHX remarkably inhibits the production of prothrombotic factors, plasminogen activator inhibitor-1 (PAI-1) and tissue factor (TF), while it upregulates the protein expression of Kruppel-like factor 2 (KLF2). The increase in PAI-1 and TF was significantly attenuated through a transgenic knockdown in KLF2 with a Lenti-shKLF2 vector. YQHX also decreases the phosphorylation of nuclear factor-κB (NF-κB) p65 and IκB following LPS stimulation, and it effectively suppresses PAI-1 and TF via a NF-κB-dependent mechanism. Taken together, our results suggest that YQHX provides a notable antithrombotic activity via regulating the KLF2 expression and NF-κB signaling pathway in HUVECs. The KLF2 and NF-κB may be potential therapeutic targets for interventions of inflammation associated with atherosclerosis.
机译:益气 - 秋雪颗粒(YQHX)是一种广泛应用于中国中医诊断“气虚”或“血瘀”治疗的中药药物。这两种症状都与炎症有关,但YQHX对炎症的机制在很大程度上是未知的。因此,我们的研究研究了YQHX对脂多糖(LPS)诱导的HUVECS诱导的炎症反应的影响。我们的数据发现,YQHX显着抑制癌细胞产生的产生,纤溶酶原激活剂抑制剂-1(PAI-1)和组织因子(TF),同时推动Kruppel样因子2(KLF2)的蛋白质表达。通过KLF2中的转基因敲低,PAI-1和TF的增加显着衰减,其中具有LENTI-SHKLF2载体。 YQHX还会降低LPS刺激后核因子-κB(NF-κB)P65和IκB的磷酸化,并且它通过NF-κB依赖性机制有效地抑制了PAI-1和TF。我们的结果表明,YQHX通过调节HUVECS中的KLF2表达和NF-κB信号传导途径提供了显着的抗血栓形成活性。 KLF2和NF-κB可能是潜在的治疗靶标,用于与动脉粥样硬化相关的炎症的干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号